Papers/PMID:40366059
Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial.
Pharmacotherapy2025The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
creatine — increases serum creatinine concentration
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×3“Specifically, there was an increase in serum creatinine (mean difference 12.63 μmol/L, 95% CI 1.14 to 24.12) and decrease in eGFR (−25.79 mL/min/1.73 m2, 95% CI −44.3 to −7.25) in individuals on creatine supplementation compared to placebo.”
Quoted verbatim from Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial.. - Study
- crossover
- Duration
- 3 months
- Dose
- creatine monohydrate ~100 mg/kg/day (2.5-10 g daily by weight band) for 12 weeks per crossover period
- Population
- children aged 5-18 years with facioscapulohumeral muscular dystrophy; safety outcome, not the primary endpoint
Effect 12.63 mean difference, 95% CI 1.14 to 24.12
creatine — decreases estimated glomerular filtration rate
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.Finding“Specifically, there was an increase in serum creatinine (mean difference 12.63 μmol/L, 95% CI 1.14 to 24.12) and decrease in eGFR (−25.79 mL/min/1.73 m2, 95% CI −44.3 to −7.25) in individuals on creatine supplementation compared to placebo.”
Quoted verbatim from Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial.. - Study
- crossover
- Duration
- 3 months
- Dose
- creatine monohydrate ~100 mg/kg/day (2.5-10 g daily by weight band) for 12 weeks per crossover period
- Population
- children aged 5-18 years with facioscapulohumeral muscular dystrophy; safety outcome, not the primary endpoint; eGFR by the modified Schwartz creatinine-based equation
Effect -25.79 mean difference, 95% CI -44.3 to -7.25